Carnitine and Liver Mitochondria Fatty Acid Processing

NCT ID: NCT03193125

Last Updated: 2022-09-29

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-05-15
• Study Completion Date: 2018-05-11

Brief Summary

This double-blind, placebo-controlled randomized trial will assess whether 14 days of oral carnitine supplementation modifies mitochondrial fatty acid processing in healthy young adults.

Detailed Description

This project will use stable isotope techniques and magnetic resonance spectroscopy (MRS) to take a first step toward clarifying how the benefit of oral carnitine supplementation depends on basal mitochondrial fatty acid processing (MFAP) and MFAP modification, with a specific focus on the liver. Approximately 24 healthy young individuals will be enrolled, with 20 expected to complete. Before and after 14 days of oral carnitine supplementation or placebo, MFAP will be measured using measures of acetyl-carnitine concentration (from long-TE proton MRS) and de novo lipogenesis (DNL, from analysis of blood metabolites following 13C-labeled acetate infusion and high-fructose drink challenge). The MFAP measures will be collected before and after loading participants with a high-fructose drink. Fructose is solely metabolized by the liver.

Conditions

Diabetes Mellitus, Type 2; Insulin Resistance; Obesity

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: QUADRUPLE

Study Groups

Carnitine

500 mg of L-carnitine to be taken 3 times a day 15 minutes before meals for 14 days.

Group Type: EXPERIMENTAL

L-Carnitine

Intervention Type: DIETARY_SUPPLEMENT

500 mg tablets of L-Carnitine taken 3 times daily before meals.

Placebo

500 mg of placebo to be taken 3 times a day 15 minutes before meals for 14 days.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DIETARY_SUPPLEMENT

500 mg tablets of L-Carnitine taken 3 times daily before meals.

Interventions

L-Carnitine

500 mg tablets of L-Carnitine taken 3 times daily before meals.

Intervention Type: DIETARY_SUPPLEMENT

Placebo

500 mg tablets of L-Carnitine taken 3 times daily before meals.

Intervention Type: DIETARY_SUPPLEMENT

Eligibility Criteria

Inclusion Criteria

• Age 20-40 years
• BMI of 24.5-35.5 kg/m2
• Willingness to eat a prescribed diet of standard meals for a total of six days
• Willingness to undergo carnitine or placebo supplementation for two weeks
• Willingness to undergo study procedures including blood draws, MRS, C13 acetate infusion, DXA, muscle biopsy, and consumption of a sugary drink over the course of 6 hours

Exclusion Criteria

• Unstable weight in the last 3 months (gain or loss >7 lb (3.2 kg)
• Significant changes in the diet or level of physical activity within the past month
• Clinical history of diabetes or cancer
• Clinically diagnosed heart, kidney, lung, thyroid, liver disease or abnormal liver enzymes that are, in the opinion of the investigator, clinically significant and represent a problem for study inclusion
• Screening fasting glucose > 125 mg/dL
• Screening blood pressure >140 systolic or >90 diastolic
• Use of certain prescribed medications at the discretion of the MI
• Smoking or use of tobacco products in the last 6 months
• Pregnancy or breastfeeding
• Clinically diagnosed neuropsychiatric conditions
• Diets that deviate extremely from the typical western diet in terms of increased meat intake are excluded, at the discretion of the MI.
• Known aversion to or refusal to drink sugary beverages
• Taking any over the counter drugs that alter the intestinal tract, at the discretion of the MI (for example, anti-cholinergic drugs and erythromycin)
• Have taken carnitine supplements regularly in the past 3 months
• Unwilling to discontinue use of dietary supplements containing significant amounts of carnitine or abstain from use one week prior to trial, at the discretion of the MI
• Women who have undergone partial hysterectomy with intact ovarian function
• Standard contra-indications to MRS, including non-removable metallic or electronic implants, claustrophobia or other fear of confinement, or inability to tolerate loud scanner noise
• Calf does not fit into the MRI coil, at the discretion of the PI
• Refusal to allow use of anonymized versions of collected data for research after this study is over

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 40 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University of Tennessee

OTHER

Sponsor Role: collaborator

Touro University

OTHER

Sponsor Role: collaborator

Pennington Biomedical Research Center

OTHER

Sponsor Role: lead

Responsible Party

Owen Carmichael

Associate Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Owen Carmichael, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Pennington Biomedical Research Center

Locations

Pennington Biomedical Research Center

Baton Rouge, Louisiana, United States

Countries

United States

Other Identifiers

PBRC 2016-076

Identifier Type: -

Identifier Source: org_study_id